View Financial HealthAnanda Pharma 배당 및 자사주 매입배당 기준 점검 0/6Ananda Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-65.5%자사주 매입 수익률총 주주 수익률-65.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 6mAnanda Pharma Delivers MRX1 Investigational Product To University Of Edinburgh Central Pharmacy For ACTiON Phase 2 Clinical TrialAnanda Pharma announced the MRX1 investigational product manufactured in 2025 has been delivered to the University of Edinburgh central pharmacy. This shipment supports the initiation of the ACTiON Phase 2 clinical trial, which is being run in partnership with the University of Edinburgh. Participant screening is now underway at the clinical trial site in preparation for first participant first dose. This milestone marks a significant step on the clinical development pathway as it brings Ananda closer to dosing its first ever Phase 2 clinical trial patient with MRX1, following the successful completion of its first in-human study earlier this year. The Company will provide further updates when first participant first dose has been confirmed. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR) as an Efficacy and Mechanism Evaluation (EME) grant, is designed to assess the efficacy and safety of MRX1 in the treatment of CIPN. It will also assess the impact of MRX1 on quality of life and health care utilisation. The trial is a double-blind, placebo controlled, crossover study with a target enrolment of 92 participants. CIPN is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of CIPN/year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University of Edinburgh.공시 • Jun 19+ 1 more updateAnanda Pharma Limited Completes Phase 1 MRX1 Pharmacokinetic Study and Confirms Favourable Safety and TolerabilityAnanda Pharma Limited has completed its Phase 1 pharmacokinetic study, yielding highly encouraging data that confirms favourable safety and tolerability and dose selection for future clinical studies. The positive outcomes of the study support continued clinical investigation into Phase 2 and provide further confidence in the Company's clinical and regulatory strategy. MRX1 demonstrated a favourable tolerability profile under the conditions evaluated in healthy volunteers following twice daily dosing for 6 days at dosing levels of 2.5 mg/kg and 7.5 mg/kg per dose under fasted conditions and following a single dose at 2.5 mg/kg under fed conditions. All reported Treatment Emergent Adverse Events ('TEAEs') were mild in severity. There were no moderate or severe TEAEs or TEAEs that led to study drug discontinuation, study withdrawal or death. There were no meaningful changes over time observed for any clinical laboratory parameter, and no abnormal clinically significant laboratory parameters were reported at any time during the study, including liver function parameters. This safety and tolerability profile was consistent with the established clinical profile of approved CBD therapies, a finding that supports the scientific rationale underpinning our FDA 505(b)(2) development pathway. The Phase 1 study was designed to assess the pharmacokinetics, safety and tolerability of multiple doses of MRX1 in healthy adult volunteers. Two dose levels were tested, 2.5 and 7.5 mg/kg of body weight. The effect of food was also assessed for lower dose level (2.5 mg/kg). A total of 20 participants received at least one dose of MRX1, with 10 participants 2.5 mg/kg twice daily and 10 receiving 7.5 mg/kg twice daily. After a 14-day wash-out period, 9 of the 10 participants who had previously been dosed with MRX1 2.5 mg/kg in Period 1 received a single dose of MRX1 2.5 mg/kg after consuming a high-fat, high-calorie meal.공시 • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.공시 • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".공시 • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ANAN.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ANAN.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Ananda Pharma 배당 수익률 vs 시장ANAN.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ANAN.F)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Pharmaceuticals)1.9%분석가 예측 (ANAN.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ANAN.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ANAN.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ANAN.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ANAN.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/23 21:35종가2025/11/26 00:00수익2025/07/31연간 수익2025/01/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Ananda Pharma Plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • 6mAnanda Pharma Delivers MRX1 Investigational Product To University Of Edinburgh Central Pharmacy For ACTiON Phase 2 Clinical TrialAnanda Pharma announced the MRX1 investigational product manufactured in 2025 has been delivered to the University of Edinburgh central pharmacy. This shipment supports the initiation of the ACTiON Phase 2 clinical trial, which is being run in partnership with the University of Edinburgh. Participant screening is now underway at the clinical trial site in preparation for first participant first dose. This milestone marks a significant step on the clinical development pathway as it brings Ananda closer to dosing its first ever Phase 2 clinical trial patient with MRX1, following the successful completion of its first in-human study earlier this year. The Company will provide further updates when first participant first dose has been confirmed. The Phase 2 trial, led by Professor Marie Fallon of The University of Edinburgh and funded by the National Institute for Health and Care Research (NIHR) as an Efficacy and Mechanism Evaluation (EME) grant, is designed to assess the efficacy and safety of MRX1 in the treatment of CIPN. It will also assess the impact of MRX1 on quality of life and health care utilisation. The trial is a double-blind, placebo controlled, crossover study with a target enrolment of 92 participants. CIPN is one of the most frequent chemotherapy side-effects but has no effective therapies and is considered a critical unmet medical need. In addition to continuing to affect patients following their cancer treatment it often means that chemotherapy dosing needs to be reduced or stopped during treatment and thus potentially increasing risk of death or duration of treatment. In the UK alone, there are more than 140,000 new cases of CIPN/year and the prevalence runs into almost a million patients. In the US there are approximately 400,000 new patients each year at an annual healthcare cost of $2.5bn. Ananda Pharma is providing its MRX1 oral solution to two Phase 2 clinical trials: ENDOCAN (endometriosis pain, funded by NHS Scotland) and ACTION (CIPN, funded by an NIHR EME grant). The Company works with world-class scientists, including Key Opinion Leaders at the University of Edinburgh.
공시 • Jun 19+ 1 more updateAnanda Pharma Limited Completes Phase 1 MRX1 Pharmacokinetic Study and Confirms Favourable Safety and TolerabilityAnanda Pharma Limited has completed its Phase 1 pharmacokinetic study, yielding highly encouraging data that confirms favourable safety and tolerability and dose selection for future clinical studies. The positive outcomes of the study support continued clinical investigation into Phase 2 and provide further confidence in the Company's clinical and regulatory strategy. MRX1 demonstrated a favourable tolerability profile under the conditions evaluated in healthy volunteers following twice daily dosing for 6 days at dosing levels of 2.5 mg/kg and 7.5 mg/kg per dose under fasted conditions and following a single dose at 2.5 mg/kg under fed conditions. All reported Treatment Emergent Adverse Events ('TEAEs') were mild in severity. There were no moderate or severe TEAEs or TEAEs that led to study drug discontinuation, study withdrawal or death. There were no meaningful changes over time observed for any clinical laboratory parameter, and no abnormal clinically significant laboratory parameters were reported at any time during the study, including liver function parameters. This safety and tolerability profile was consistent with the established clinical profile of approved CBD therapies, a finding that supports the scientific rationale underpinning our FDA 505(b)(2) development pathway. The Phase 1 study was designed to assess the pharmacokinetics, safety and tolerability of multiple doses of MRX1 in healthy adult volunteers. Two dose levels were tested, 2.5 and 7.5 mg/kg of body weight. The effect of food was also assessed for lower dose level (2.5 mg/kg). A total of 20 participants received at least one dose of MRX1, with 10 participants 2.5 mg/kg twice daily and 10 receiving 7.5 mg/kg twice daily. After a 14-day wash-out period, 9 of the 10 participants who had previously been dosed with MRX1 2.5 mg/kg in Period 1 received a single dose of MRX1 2.5 mg/kg after consuming a high-fat, high-calorie meal.
공시 • Mar 05Ananda Pharma Receives MHRA And NHS Ethics Approval For Endocan Phase 2 Clinical Trial For EndometriosisAnanda Pharma has received NHS Health Research Authority (HRA) and MHRA approval for the ENDOCAN Phase 2 clinical trial investigating the safety and efficacy of its proprietary MRX1 CBD oral solution, for the management of endometriosis-associated pain. The Phase 2 trial, led by Dr Lucy Whitaker as Principal Investigator, Prof Andrew Horne and Prof Phillipa Saunders of The University of Edinburgh and funded by the Chief Scientist Office, is a double-blind, placebo controlled pilot study to assess the effectiveness of MRX1 CBD oral solution to alleviate pain and improve quality of life for women with endometriosis. The study will randomise up to 100 women diagnosed with endometriosis over a treatment period of 12 weeks. The trial will be conducted through NHS Lothian and NHS Grampian in Scotland. Endometriosis is a chronic condition affecting ~190 million women. It is defined by the presence of endometrial-like tissue outside the uterus ('lesions'), commonly within the pelvis. Endometriosis costs the UK ~£8.2 billion per year in NHS costs and lost income. The cost of endometriosis in the US is estimated at more than $100 billion per year when taking into account treatment, lost productivity and wider family and societal costs. Current treatment options include surgical excision of the lesions, treatment with hormone suppressing drugs, various analgesics and anti depressants. These treatments are often ineffective and come with harmful side effects. Symptoms recur within five years following surgery in 40-50% of women. There is an urgent unmet need for new medical treatments for endometriosis and optimal treatment for endometriosis was a key strategic priority of the 2021 Scottish Government's Women's Health Plan. The dosing in this trial will go as high as 12.5mg/kg/day of CBD which for a 70kg woman would be 875mg of CBD per day. For comparison, the UK Food Standards Authority recommends a maximum daily dose of 10mg per person and other clinical trials investigating CBD for the treatment of endometriosis pain considered much lower doses. It is important to note that MRX1 CBD oral solution is effectively THC free meaning it can be dosed at high levels without concerns of intoxication. Approval from the MHRA and HRA Ethics Committee is a key regulatory milestone, enabling the trial to proceed to patient recruitment and site initiation activities. Further updates will be provided as the study progresses.
공시 • Nov 24Ananda Pharma Plans to Delist from Aquis Stock ExchangeAnanda Pharma PLC Board proposes to de-list the company from Aquis Stock Exchange and become a private company, citing the cost of maintaining a listing and a dearth of liquidity for its shares. Ananda Pharma calls a general meeting of shareholders for December 12 to approve the plan. "As you know I have funded Ananda with more than GBP 10 million over the past 8 years," explains Executive Chair Charles Morgan. "Despite our best efforts, we have not managed to gain the funding support of the public markets, so we intend to delist the company while we progress MRX1 development and our clinical trials. This move will save Ananda around GBP 500,000 per annum".
공시 • Jul 31Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025Ananda Pharma Plc, Annual General Meeting, Aug 26, 2025. Location: the offices of arch law, level 2, huckletree, 8 bishopsgate, london, ec2n 4bq United Kingdom